Abstract
Ninety-five children and adolescents with their first relapse of ALL were treated in the multicentric prospective trial ALL-REZ BFM 83. Treatment was stratified with respect to time and site of relapse. The overall remission rate was 86.3%. In the group of patients with early relapse only 44/56 children (78.6%) achieved a second remission, whereas the remission rate was 97.4% (38/39) in patients with late relapse. The 2 year probabilities of a sustained second complete remission are 0.65 +/- 0.10, 0.33 +/- 0.09 and 0.71 +/- 0.14 for patients with late, early and isolated CNS relapses, respectively. The poorest prognosis was observed in children with early marrow relapse (0.16 +/- 0.13 after one year).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have